Cas9 Stable Cell Line - HL-1

The HL-1 cell line is a cardiomyocyte line derived from AT-1 mouse atrial cardiomyocytes, renowned for its ability to maintain differentiated phenotypes, including spontaneous contraction and expression of heart-specific markers. The Cas9-stable cell line - HL-1 is a genetically engineered variant in which CRISPR-associated protein 9 (Cas9) is stably integrated into the HL-1 genome. This modification enables precise, targeted genome editing without transient transfection, ensuring consistent Cas9 expression across different cell populations. This cell line retains key features of HL-1, such as sarcomere structure and electrophysiological properties, while providing a robust platform for CRISPR-based experiments. Its stability reduces experimental variability and simplifies workflows, making it ideal for long-term studies such as cardiac biology, disease modeling, and drug screening.

The Cas9-stable cell line - HL-1 holds broad promise for applications in cardiovascular research and therapeutic development. This cell line enables efficient gene knockout, knock-in, and transcriptional regulation within a physiologically relevant cardiac environment, supporting research on cardiac development, hypertrophy, arrhythmias, and metabolic disorders. Researchers have used this cell line to accelerate the target validation of novel therapies by introducing patient-specific mutations to mimic inherited heart diseases such as cardiomyopathy or ion channelopathies. It also supports large-scale CRISPR screening to identify genes involved in heart cell survival, contractility, and drug response. In drug development, this cell line can rapidly assess the efficacy and toxicity of compounds on genetically modified heart cells, thereby reducing reliance on animal models.